<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135329</url>
  </required_header>
  <id_info>
    <org_study_id>J1046</org_study_id>
    <secondary_id>NA_00039363</secondary_id>
    <nct_id>NCT01135329</nct_id>
  </id_info>
  <brief_title>Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers</brief_title>
  <official_title>Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to learn more about reduced-intensity bone marrow transplantation
      (BMT), also known as a &quot;mini&quot; transplant for patients with blood cancers, using bone marrow
      from a relative.

      The main goal of the study is to determine how quickly the donor's bone marrow &quot;takes&quot; in
      your body. Other goals include describing how many people accept the bone marrow and how
      quickly the blood counts come up; describing Graft-versus-host disease (GVHD) and other
      complications; and describing how many people survive without progressive cancer and survive
      overall
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the present time there are few or no cures for people with cancer of the blood or lymph
      glands outside of a bone marrow transplant (BMT). BMT has developed over several decades of
      research as an effective treatment of various malignant and nonmalignant hematologic
      diseases.

      This research is being done to learn more about reduced-intensity bone marrow transplantation
      (BMT), also known as a &quot;mini&quot; transplant for patients with blood cancers, using bone marrow
      from a relative. The bone marrow for this transplant comes from a relative who is a
      half-match or &quot;haplo&quot; match to you. Possible donors include parents, siblings, and children.

      &quot;Mini&quot; transplants have been given to many people with various cancers but are considered
      experimental. Over 200 people at Johns Hopkins have received mini transplants with high doses
      of cyclophosphamide after the transplant. However, the chemotherapy combination and other
      treatment given before those transplants were different from what is in this study. Although
      all of the chemotherapy and immune-lowering drugs used in this study are approved by the Food
      and Drug Administration (FDA), the combination of medications used in this study are not FDA
      approved and are experimental.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The stopping rule was met and hence the study was closed
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the proportion of patients achieving full donor chimerism</measure>
    <time_frame>Day 60</time_frame>
    <description>After reduced-intensity, partially (Human leukocyte antigen) HLA-mismatched or HLA-matched BMT with fludarabine, busulfan, and post-grafting immunosuppression that includes high-dose cyclophosphamide, estimate the proportion achieving full donor chimerism by Day 60 in unsorted and CD3+ sorted peripheral blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease (GVHD)</measure>
    <time_frame>Day 60</time_frame>
    <description>Estimate the cumulative incidence of acute and chronic Graft-versus-host disease (GVHD), and describe other major toxicities.</description>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,</intervention_name>
    <description>Fludarabine 30 mg/m2 IV once a day for 4 days Busulfan 0.8 mg/kg IV every 12 hours for 4 days Cyclophosphamide 50 mg/kg IV daily for 2 days</description>
    <other_name>BMT</other_name>
    <other_name>Allogeneic</other_name>
    <other_name>Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-degree related donor who is at minimum HLA haploidentical

          -  Eligible diagnoses:

               1. Low-grade non-Hodgkin's lymphoma or plasma cell neoplasm that has progressed
                  during multiagent therapy, failed at least two prior therapies (excluding single
                  agent rituximab and single agent steroids), or in the case of lymphoma undergone
                  histological conversion:

                    -  Follicular grade 1 or 2 lymphoma

                    -  Follicular lymphoma not otherwise specified

                    -  Marginal zone (or MALT) lymphoma

                    -  Lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia

                    -  Hairy cell leukemia

                    -  Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL)

                    -  Prolymphocytic leukemia

                    -  Low grade B-cell lymphoma, unspecified

                    -  Multiple myeloma

                    -  Plasma cell leukemia

               2. Poor-risk SLL or CLL, defined by an 11q or 17p deletion, histological conversion,
                  or disease progression &lt; 6 months after a purine analog-containing regimen

               3. Aggressive lymphoma that has failed at least one prior regimen of multiagent
                  chemotherapy, and patient is either ineligible for autologous BMT or autologous
                  BMT is not recommended:

                    -  Hodgkin lymphoma

                    -  Follicular grade 3 lymphoma

                    -  Mantle cell lymphoma or leukemia

                    -  Diffuse large B-cell lymphoma (excluding primary CNS lymphoma). Eligible
                       subtypes include primary mediastinal large B-cell lymphoma, T-cell rich
                       large B-cell lymphoma, and large B-cell lymphoma not otherwise specified.

                    -  Burkitt's lymphoma/leukemia

                    -  Atypical Burkitt's lymphoma/leukemia (high grade B-cell lymphoma,
                       unclassified, including that with features intermediate between Burkitt's
                       and diffuse large B-cell lymphoma)

                    -  Anaplastic large cell lymphoma

                    -  Plasmablastic lymphoma

                    -  Peripheral T-cell lymphoma

               4. Relapsed or refractory acute leukemia in second or subsequent remission

               5. Poor-risk acute leukemia in first remission

               6. AML with at least one of the following:

                    -  AML arising from MDS or a myeloproliferative disorder, or secondary AML

                    -  Presence of Flt3 internal tandem duplications

                    -  Poor-risk cytogenetics

                    -  Primary refractory disease

                         -  ALL (leukemia and/or lymphoma) with at least one of the following:

                    -  Adverse cytogenetics

                    -  Clear evidence of hypodiploidy

                    -  Primary refractory disease

                         -  Biphenotypic leukemia

                         -  MDS with at least one of the following features:

                         -  Poor-risk cytogenetics

                         -  IPSS score of INT-2 or greater

                         -  Treatment-related MDS

                         -  MDS diagnosed before age 21 years

                         -  Progression on or lack of response to standard DNA-methyltransferase
                            inhibitor therapy

                         -  Life-threatening cytopenias, including those generally requiring
                            greater than weekly transfusions

               7. Interferon- or imatinib-refractory CML in first chronic phase, or non-blast
                  crisis CML beyond first chronic phase

               8. Philadelphia chromosome negative myeloproliferative disease (including
                  myelofibrosis)

               9. Chronic myelomonocytic leukemia

              10. Juvenile myelomonocytic leukemia

                    -  For patients with SLL, CLL, or prolymphocytic leukemia, &lt; 20% of bone marrow
                       cellularity involved by this process

                    -  Adequate end-organ function:

          -  Left ventricular ejection fraction greater than or equal to 35%

          -  Bilirubin â‰¤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST
             &lt; 5 x ULN

          -  FEV1 and FVC &gt; 40% of predicted; or in pediatric patients, if unable to perform
             pulmonary function tests due to young age, oxygen saturation &gt;92% on room air

               -  ECOG performance status &lt; 2 or Karnofsky or Lansky score &gt; 60

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Uncontrolled infection Note: Infection is permitted if there is evidence of response
             to medication. Eligibility of HIV infected patients will be determined on a
             case-by-case basis.

          -  Any previous BMT within 3 months prior to start of conditioning

          -  Active extra-medullary leukemia or known active Central Nervous System (CNS)
             involvement by malignancy. Such disease treated into remission is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette Kasamon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sydney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Non hodgkin's lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Acute lymphoblastic leukemia(ALL)</keyword>
  <keyword>Chronic myeloid leukemia (CML)</keyword>
  <keyword>Chronic Myelomonocytic (CMML)</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>High-risk acute leukemia in first remission</keyword>
  <keyword>Relapsed leukemia in remission</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>High-dose cyclophosphamide</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Nonmyeloablative</keyword>
  <keyword>Reduced intensity</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Bone marrow transplant (BMT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 22, 2014</submitted>
    <returned>September 3, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

